Please assess the completion status of the following clinical trial:

Trial Title: New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~≥ 50 years of age or older at the time of enrollment~Willing to sign the informed consent form~Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient):~FBG ≥126mg/dl HbA1c ≥6.5% RBG ≥ 200mg/dl 2-hour post-glucose ≥200mg/dl (OGTT)~Must have had glycemic parameter measured in 3-18 months prior to screening that did NOT meet DM criteria~Must be willing to provide several tubes of blood without endangering health~No history of pancreatic cancer or other known pancreatic neoplasia~No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment and in situ cancers)~Exclusion Criteria:~Prior DM diagnosis~Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll)~Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment~Any known pancreatic lesions (aside from diabetes)~Received cancer treatment within the past 5 years (with the exception of treatment of non-melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence.~Current chronic or acute oral steroid use~History of intra-articular steroid injections (\<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide)~Any surgery requiring general anesthesia within 2 months of collection~Local anesthetic (including dental novocaine) within 1 week of collection~History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD)~Blood transfusion within 1 month~Organ transplant recipient~Currently pregnant, or pregnancy within last 12 months~Receipt of systemic immunomodulation therapy within past 12 months~Significant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pancreatic Cancer Signal Detection = Detected (Type: OTHER): Subjects with test results detected will undergo MRI/Imaging
- Pancreatic Cancer Signal Detection = Not Detected (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).